WeightWatchers gets into prescription weight loss business

“It is our responsibility, as the trusted leader in weight management, to support those interested in exploring if medications are right for them,” said CEO Sima Sistani said in a prepared statement late Monday.

Ozempic manufacturer Novo Nordisk says that it’s not a weight loss drug. It’s used to improve blood sugar in adults with type 2 diabetes, along with diet and exercise, but can also help patients lose some weight. If it’s not treated, obesity can lead to lifelong health problems, including high blood pressure, diabetes and depression.

The estimated annual medical cost of obesity in the U.S. was almost $173 billion in 2019 dollars, according to the CDC. Annual medical costs for adults who had obesity were $1,861 higher than medical costs for people with healthy weight.

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว

Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้

WSJ News Exclusive | WeightWatchers Moves Into the Ozempic Market With Telehealth DealThe weight-management company is buying digital health company Sequence, which offers telehealth visits with doctors. Isn't moving into the Ozempic market an implicit admission that their product doesn't work. 'You can totally lose weight and keep it off with our points system... but on second thought, here's some drugs.' 황금으로 만든 골든 이글이 필요해
แหล่ง: WSJhealth - 🏆 413. / 53 อ่านเพิ่มเติม »

WeightWatchers Moves Into the Ozempic Market With Telehealth DealThe weight-management company is buying digital health company Sequence, which offers telehealth visits with doctors.
แหล่ง: WSJhealth - 🏆 413. / 53 อ่านเพิ่มเติม »

Meta shares rise after new wave of layoffs, WeightWatchers' stock makes gains after results and acquisition; Grindr's stock falls after profit dropMeta shares rise after new wave of layoffs, WeightWatchers’ stock makes gains after results and acquisition; Grindr’s stock falls after profit drop
แหล่ง: MarketWatch - 🏆 3. / 97 อ่านเพิ่มเติม »